1422528-30-0
Chemical Structure
PAIB-SOs-12
- CAS No.: 1422528-30-0
- Formula:C20H22Cl2N2O4S
- Molecular Weight:457.37
InChIKey: BUJXPRDHAJNAMY-UHFFFAOYSA-N
SMILES: O=C1N(CCN1CCCCC)C2=CC=C(S(=O)(OC3=CC(Cl)=CC(Cl)=C3)=O)C=C2
Biological Activity: PAIB-SOs-12 is a CYP1A1-activated antimitotic prodrug with affinity for human CYP1A1, with a Ki value of 1.2 μM. PAIB-SOs-12 exhibits nanomolar antiproliferative activity in cancer cells expressing CYP1A1, with a selectivity ratio of over 100 against cancer cells that do not express CYP1A1. PAIB-SOs-12 undergoes CYP1A1-mediated N-dealkylation to form the active metabolite PIB-SO, which induces G2/M cell cycle arrest and microtubule disruption, and shows significantly improved stability in rodent liver microsomes compared to its n-butyl analog. PAIB-SOs-12 can be used in breast cancer-related research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PAIB-SOs-12 | PAIB-SOs-12 is a CYP1A1-activated antimitotic prodrug with affinity for human CYP1A1, with a Ki value of 1.2 μM. PAIB-SOs-12 exhibits nanomolar antiproliferative activity in cancer cells expressing CYP1A1, with a selectivity ratio of over 100 against cancer cells that do not express CYP1A1. PAIB-SOs-12 undergoes CYP1A1-mediated N-dealkylation to form the active metabolite PIB-SO, which induces G2/M cell cycle arrest and microtubule disruption, and shows significantly improved stability in rodent liver microsomes compared to its n-butyl analog. PAIB-SOs-12 can be used in breast cancer-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Chavez Alvarez AC, et al. Homologation of the Alkyl Side Chain of Antimitotic Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonate Prodrugs Selectively Targeting CYP1A1-Expressing Breast Cancers Improves Their Stability in Rodent Liver Microsomes. Journal of medicinal chemistry. 2023 Feb 23;66(4):2477-2497. [Content Brief]
Keywords
